MedTrace Logo

A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body

NCT02014116 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2019-12-27

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.

Conditions

  • Neoplasms
  • Neoplasm Metastasis
  • Melanoma
  • Carcinoma, Non-Small-Cell Lung
  • Colorectal Neoplasms

Interventions

DRUG

LY3009120 capsule

Administered orally.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-26
Primary Completion
2017-04-07
Completion
2018-10-05

Countries

  • United States
  • Australia
  • France
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02014116 on ClinicalTrials.gov